uniQure news

uniQure

UniQure's GAAP loss for 3 months of 2022 was $46.678 million, up 12.3% from $41.556 million in the previous year. Revenues increased 3.9 times to $1.792 million from $0.454 million a year earlier.

uniQure

UniQure's GAAP net income for 2021 was $329.589 million, compared to a loss of $125.024 million in the previous year. Revenues increased 13.96 times to $524.002 million from $37.514 million a year earlier.

uniQure

UniQure's GAAP loss for Q3 2021 was $36.531 million, down 32.1% from $53.775 million in the prior year. Revenue increased 11.2% to $1,989 million compared to $1,789 million a year earlier.

uniQure

UniQure's GAAP net income for Q2 2021 was $399.468 mln, compared to a loss of $42.551 mln in the previous year. Revenues increased 302 times to $463.868 million from $1.535 million a year earlier.

uniQure

UniQure acquires Corlive Therapeutics business for $46.3 million Corlive Therapeutics specializes in developing new treatments for neurological disorders. The deal is expected to close in early Q3 2021.

uniQure

UniQure's GAAP loss for 3 months of 2021 was $41.556 million, up 48.4% from $27.999 million in the previous year. Revenue increased 4.4 times to $454,000 from $104,000 a year earlier.

uniQure

UniQure's GAAP loss for 2020 was $125.024 million, up 0.7% from $124.201 million in the previous year. Revenue increased 5.1 times to $37.514 million from $7.281 million a year earlier.

uniQure

uniQure's GAAP loss in Q3 2020 amounted to $53.775 million, having doubled compared to $23.604 million in the previous year. Revenue increased 71% to $1.789 million, against $1.046 million a year earlier.